胃黏膜肠化内镜分级可替代组织学评估早期胃肿瘤风险吗?
单中心病例对照研究纳入187例内镜治疗的早期胃肿瘤患者与187例年龄性别匹配对照,比较EGGIM、OLGA和OLGIM对早期胃肿瘤的风险分层价值。多因素分析显示三种系统均与风险独立相关,EGGIM≥5在病例组占68.6%而对照组13.3%,提示内镜分级或可简化实践并减少活检需求。
要点
- EGGIM≥5在早期胃肿瘤患者中占68.6%,显著高于对照组的13.3%。
- OLGA III/IV和OLGIM III/IV在病例组分别占68%和61%,均显著高于对照组。
- 多因素分析中仅三种分级系统与早期胃肿瘤风险显著相关。
核心结论
- 组织学评估是胃癌独立危险因素,而胃黏膜肠化内镜分类与早期胃肿瘤高度相关。
- 经进一步前瞻性验证后,内镜分类或可用于胃癌风险分层并减少活检需求。
研究设计与样本
- 单中心病例对照研究,纳入187例经内镜治疗的早期胃肿瘤患者和187例年龄、性别匹配的对照。
- 按EGGIM、OLGA和OLGIM系统对个体分类,评估胃炎症分期及其他临床参数与早期胃肿瘤风险的关系。
主要发现
- 早期胃肿瘤患者EGGIM≥5的比例为68.6%,显著高于对照组的13.3%(p<0.001)。
- OLGA III/IV期在病例组占68%、对照组占11%(p<0.001)。
- OLGIM III/IV期在病例组占61%、对照组占3%(p<0.001)。
- 多因素分析中EGGIM 1-4的AOR为12.9(95%CI 1.4–118.6),EGGIM 5-10的AOR为21.2(95%CI 5.0–90.2)。
- OLGA I/II的AOR为5.0(95%CI 0.56–44.5),OLGA III/IV的AOR为11.1(95%CI 3.7–33.1)。
临床怎么用
- 内镜EGGIM分级有望用于胃癌风险分层,减少对活检组织学评估的依赖。
- 该分类需经进一步前瞻性验证后才适合推广至日常实践。
局限性
- 单中心病例对照设计,证据等级有限,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the value of endoscopic grading of gastric intestinal metaplasia (EGGIM), operative link on gastritis assessment (OLGA) and operative link on gastric intestinal metaplasia (OLGIM) on risk stratification for early gastric neoplasia (EGN) and to investigate other factors possibly associated with its development. DESIGN: Single centre, case-control study including 187 patients with EGN treated endoscopically and 187 age-matched and sex-matched control subjects. Individuals were classified according to EGGIM, OLGA and OLGIM systems. EGN risk according to gastritis stages and other clinical parameters was further evaluated. RESULTS: More patients with EGN had EGGIM of ≥5 than control subjects (68.6% vs 13.3%, p<0.001). OLGA and OLGIM stages III/IV were more prevalent in patients with EGN than in control subjects (68% vs 11%, p<0.001, and 61% vs 3%, p<0.001, respectively). The three systems were the only parameters significantly related to the risk of EGN in multivariate analysis: for EGGIM 1-4 (adjusted OR (AOR) 12.9, 95% CI 1.4 to 118.6) and EGGIM 5-10 (AOR 21.2, 95% CI 5.0 to 90.2); for OLGA I/II (AOR 5.0, 95% CI 0.56 to 44.5) and OLGA III/IV (AOR 11.1, 95% CI 3.7 to 33.1); for OLGIM I/II (AOR 11.5, 95% CI 4.1 to 32.3) and OLGIM III/IV (AOR 16.0, 95% CI 7.6 to 33.4). CONCLUSION: This study confirms the role of histological assessment as an independent risk factor for gastric cancer (GC), but it is the first study to show that an endoscopic classification of gastric intestinal metaplasia is highly associated with that outcome. After further prospective validation, this classification may be appropriate for GC risk stratification and may simplify every day practice by reducing the need for biopsies.
引用
- Marcos P, Brito-Gonçalves G, Libânio D, et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut. 2020. PMID: 32051208. doi:10.1136/gutjnl-2019-320091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。